Literature DB >> 23554501

PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors.

Miriam Melis1, Simona Scheggi, Gianfranca Carta, Camilla Madeddu, Salvatore Lecca, Antonio Luchicchi, Francesca Cadeddu, Roberto Frau, Liana Fattore, Paola Fadda, M Grazia Ennas, M Paola Castelli, Walter Fratta, Bjorn Schilstrom, Sebastiano Banni, M Graziella De Montis, Marco Pistis.   

Abstract

Ventral tegmental area dopamine neurons control reward-driven learning, and their dysregulation can lead to psychiatric disorders. Tonic and phasic activity of these dopaminergic neurons depends on cholinergic tone and activation of nicotinic acetylcholine receptors (nAChRs), particularly those containing the β2 subunit (β2*-nAChRs). Nuclear peroxisome proliferator-activated receptors type-α (PPARα) tonically regulate β2*-nAChRs and thereby control dopamine neuron firing activity. However, it is unknown how and when PPARα endogenous ligands are synthesized by dopamine cells. Using ex vivo and in vivo electrophysiological techniques combined with biochemical and behavioral analysis, we show that activation of α7-nAChRs increases in the rat VTA both the tyrosine phosphorylation of the β2 subunit of nAChRs and the levels of two PPARα endogenous ligands in a Ca(2+)-dependent manner. Accordingly, in vivo production of endogenous PPARα ligands, triggered by α7-nAChR activation, blocks in rats nicotine-induced increased firing activity of dopamine neurons and displays antidepressant-like properties. These data demonstrate that endogenous PPARα ligands are effectors of α7-nAChRs and that their neuromodulatory properties depend on phosphorylation of β2*-nAChRs on VTA dopamine cells. This reveals an autoinhibitory mechanism aimed at reducing dopamine cell overexcitation engaged during hypercholinergic drive. Our results unveil important physiological functions of nAChR/PPARα signaling in dopamine neurons and how behavioral output can change after modifications of this signaling pathway. Overall, the present study suggests PPARα as new therapeutic targets for disorders associated with unbalanced dopamine-acetylcholine systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23554501      PMCID: PMC6618938          DOI: 10.1523/JNEUROSCI.4647-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

2.  α7 nicotinic receptor full agonist reverse basolateral amygdala hyperactivity and attenuation of dopaminergic neuron activity in rats exposed to chronic mild stress.

Authors:  Gilda A Neves; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-10-12       Impact factor: 4.600

3.  Prenatal and childhood exposure to per- and polyfluoroalkyl substances (PFASs) and child cognition.

Authors:  Maria H Harris; Emily Oken; Sheryl L Rifas-Shiman; Antonia M Calafat; Xiaoyun Ye; David C Bellinger; Thomas F Webster; Roberta F White; Sharon K Sagiv
Journal:  Environ Int       Date:  2018-04-26       Impact factor: 9.621

4.  PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission.

Authors:  Giordano de Guglielmo; Miriam Melis; Maria Antonietta De Luca; Marsida Kallupi; Hong Wu Li; Kevin Niswender; Antonio Giordano; Martina Senzacqua; Lorenzo Somaini; Andrea Cippitelli; George Gaitanaris; Gregory Demopulos; Ruslan Damadzic; Jenica Tapocik; Markus Heilig; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2014-09-14       Impact factor: 7.853

5.  Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse.

Authors:  Zuzana Justinova; Leigh V Panlilio; Guillermo Moreno-Sanz; Godfrey H Redhi; Alessia Auber; Maria E Secci; Paola Mascia; Tiziano Bandiera; Andrea Armirotti; Rosalia Bertorelli; Svetlana I Chefer; Chanel Barnes; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2015-03-10       Impact factor: 7.853

6.  In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.

Authors:  Asti Jackson; Deniz Bagdas; Pretal P Muldoon; Aron H Lichtman; F Ivy Carroll; Mark Greenwald; Michael F Miles; M Imad Damaj
Journal:  Neuropharmacology       Date:  2017-03-07       Impact factor: 5.250

7.  Age-related changes in nicotine response of cholinergic and non-cholinergic laterodorsal tegmental neurons: implications for the heightened adolescent susceptibility to nicotine addiction.

Authors:  Mark H Christensen; Masaru Ishibashi; Michael L Nielsen; Christopher S Leonard; Kristi A Kohlmeier
Journal:  Neuropharmacology       Date:  2014-05-24       Impact factor: 5.250

Review 8.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

9.  Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.

Authors:  Marco Calabrò; Stefano Porcelli; Concetta Crisafulli; Sheng-Min Wang; Soo-Jung Lee; Changsu Han; Ashwin A Patkar; Prakash S Masand; Diego Albani; Ilaria Raimondi; Gianluigi Forloni; Sofia Bin; Carlotta Cristalli; Vilma Mantovani; Chi-Un Pae; Alessandro Serretti
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

Review 10.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.